title: [Human immunodeficiency virus infection and viral hepatitis].
abstract: Hepatic complications currently represent one of the leading reasons for medical consultations, hospitalisation, and death in the HIV-infected population. This is due to a large extent to viral hepatitis, given its disproportionate frequency in this population. Chronic hepatitis B affects 5-10% of the HIV-infected population. Vaccination has reduced the incidence of liver disease related to hepatitis-B virus (HBV), and the availability of tenofovir has dramatically improved the prognosis of HIV/HBV carriers. Delta hepatitis affects around 15% of HIV-infected individuals in Europe harbouring positive HBsAg. It has the worst prognosis, given its accelerated course to cirrhosis and the absence of successful therapy. Lastly, chronic hepatitis C is the major cause of liver disease in the HIV population. Although classically linked to persons infected parenterally (i.e., intravenous drug users), outbreaks of acute hepatitis C among homosexual men have been reported over the last decade. Treatment with pegylated interferon plus ribavirin provides a cure in less than 40% of patients. However, the introduction of new direct acting antivirals against hepatitis- C virus (HCV) (telaprevir, boceprevir) has revolutionised the field, as HAART did in 1996 in the HIV field, improving the prognosis of co-infected patients. However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population.
authors: Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, España. vicenc.soriano@gmail.com
authors: Vicente
authors: V
authors: Soriano
authors: Luz
authors: L
authors: Martin-Carbonero
authors: Eugenia
authors: E
authors: Vispo
authors: Pablo
authors: P
authors: Labarga
authors: Pablo
authors: P
authors: Barreiro
mesh_terms: D000465:Algorithms; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015897:Comorbidity; D018450:Disease Progression; D004347:Drug Interactions; D016903:Drug Monitoring; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D003699:Hepatitis D / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008297:Male; D011379:Prognosis; D012008:Recurrence
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents